Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy. These ITT data were presented today in two late breaker oral presentations at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Results showed that, on an ITT basis,

  • Approximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%; and
  • Obese patients on Contrave demonstrated significant improvements in important markers of cardiometabolic risk including waist circumference, HDL and triglycerides

"The data presented today and on Saturday provide a deeper view of Contrave, and what we believe is a balanced efficacy and safety profile," said Eduardo Dunayevich, M.D., Chief Medical Officer of Orexigen. "These findings should help clinicians assess the potential value of Contrave pharmacotherapy in managing obesity and support our belief that if approved, Contrave could meet the broad range of needs of this patient population by virtue of its efficacy, safety and benefits on key markers of cardiometabolic risk."

Additional data from today's late breaker presentations are outlined in the below table: 

    Efficacy Result(+)
                                    COR-I                       COR-II
    --------------------------------------------------------------------------
                               PBO 
'/>"/>
SOURCE  Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Research ... and outcomes research also   to   be presented ... SHPG ), the global specialty biopharmaceutical company, announces ... presentations at the American Psychiatric Association (APA) 166th Annual ... 18-22. The data being presented represent Shire,s ongoing commitment ...
(Date:5/17/2013)... LAKES, Fla. , May 17, 2013 Fuse ... and delivery technology company that is developing new, patent-pending technologies ... minerals, announced today that it will hold a business update ... Wednesday, May 22 nd , 2013 at 4:30 PM ET. ... Tuffin will host the call and will be ...
(Date:5/17/2013)... 2013 Oramed Pharmaceuticals Inc. (NASDAQCM: ... delivery systems, announced today that the United States Food ... New Drug application(IND) for ORMD-0801, its oral insulin capsule. ... FDA clearance to proceed," stated Nadav Kidron ... a major milestone for Oramed and we look forward ...
Breaking Medicine Technology:Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 2Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 3Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 4Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 5Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 6Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 7Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 8Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 9Shire to Present Scientific Data Across a Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting 10Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
(Date:5/18/2013)... published an original art book for iPad with tango as ... who share their creations based on the traditional music genre ... iPad . , This work gathers more than 150 ... signature idiosyncrasy and passion of tango. Such book is ... it includes a free trailer of the book for readers ...
(Date:5/18/2013)... There are significant cost and risk factors ... or treat gastrointestinal problems, according to research presented ... study by New York Presbyterian Hospital and Weill-Cornell ... substantially reduce the cost and risk of managing ... to affect nearly 25 percent of adults, researchers ...
(Date:5/18/2013)... In a May 14, 2013 article entitled ... Discovering Cancer Gene,” Fox News reported the movie star ... she carried a gene that doctors estimated gave her ... 50 percent risk of ovarian cancer (go to: goo.gl/5JHBP). ... 2013 with a blog post entitled “A Patient’s Journey: ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) A ground-breaking ... colorectal care, according to research presented today at ... optimizing the minimal withdrawal time for colonoscopies and ... , During colonoscopy, doctors use a device called ... test for colorectal cancer allows a doctor to ...
(Date:5/18/2013)... York (PRWEB) May 18, 2013 ... mesh products continue to move forward in a consolidated ... Bernstein Liebhard LLP reports. According to a notice on ... the Ethicon pelvic mesh litigation will be held on ... complaints have been filed in the proceeding on behalf ...
Breaking Medicine News(10 mins):Health News:New Art Book for iPad: Tango Art 2Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Angelina Jolie – Scarless Breast Augmentation Surgery 2Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3
... kidney failure in men.// ,The researchers had taken 473 ... a glass a day) and compared their elevated creatinine levels ... than a glass a day of alcohol. The research had ... through a period of 14 years. ,The results of ...
... UCLA had been able to isolate a biomarker for prostate ... the disease. ,The biomarker protein, which was hidden inside ... from where it can go into the blood. This will ... prostate cancer disease with both chemotherapy and immunotherapy, for better ...
... been associated to cardiovascular diseases and recent study says that// ... have always been carried on to find out the effect ... new study was done to find out the effect of ... ,In cocaine users undergoing coronary angiography, there was evidence of ...
... scan reports have suggested that a new gene may ... depression. ,People having the gene that controls depression ... the mood regulating circuit. This gene may be affecting ... the emotion of fear, and cingulated, another part of ...
... in man, a disease called AIDS.// Scientists are now convinced ... do fight back against the virus. ,The new research, ... a small amount of body’s antibodies are successful in fighting ... extent. ,Till date the treatment of AIDS had ...
... the blood can increase the risk of having testicular cancer ... of British Journal of Cancer says that the increase in ... by almost as much as 4.5 % than for people ... from Karolinska University Hospital had looked into the data of ...
Cached Medicine News:
Nidek offers 3-Dx Digital stereo camera to provide a complete and comprehensive digital imaging platform....
Measurement of progressive multi-focal lenses is fast and easy with the CLM-3000 auto-lensmeter. The data is represented in a simple to understand bar graphic display....
Auto Lensmeter LM-970...
Autolensmeter with black/white monitor and no internal printer....
Medicine Products: